- TransCode Therapeutics Inc (NASDAQ:RNAZ) has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138.
- TTX-MC138 is TransCode's lead therapeutic candidate for the treatment of metastatic solid tumors.
- The award totals $2.3 million expected over three years.
- TransCode expects to file IND in Q1 of 2022. TransCode's proprietary TTX platform leverages an iron oxide nanoparticle as a novel, image-guided system to safely and efficiently deliver oligonucleotides to their intended RNA target. TTX-MC138 targets MicoRNA-10b believed to drive metastatic disease.
- Price Action: RNAZ shares are up 4.27% at $3.41 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
